China monoclonal antibodies market is estimated to grow at a CAGR of 9.2% during the forecast period. A significant rise in cancer incidences and increasing launches of biosimilars are some potential factors accelerating market growth. To increase access to potential oncology treatment, the Chinese authorities have been granted approvals of monoclonal antibodies. For instance, in January 2020, Bio-Thera Solutions, Ltd. declared that China National Medical Products Administration (NMPA) launched QLETLI, a biosimilar to Humira (adalimumab). 

Visit for Global Monoclonal Antibodies Market Report at: https://www.omrglobal.com/industry-reports/monoclonal-antibodies-market

It is the first adalimumab biosimilar granted by the NMPA which is indicated to treat three autoimmune diseases, which include ankylosing spondylitis, plaque psoriasis, and rheumatoid arthritis. It is the company’s first biosimilar gained regulatory approval, and it is the second biosimilar which is approved in China by the NMPA. The company is developing multiple additional planned biosimilars, which include biosimilars to Avastin and to Actemra/RoActemra. These are both currently being assessed in global Phase III clinical trials. The company is also pursuing biosimilars to Stelara and Simponi. 

China monoclonal antibodies market is segmented based on source and application. Based on the source, the market is classified into murine, chimeric, human, and humanized. Based on the application, the market is classified into cancer, infectious diseases, auto-immune diseases, inflammatory diseases, and others. In 2019, monoclonal antibodies find significant application in cancer treatment as targeted and immunotherapy to find and attack cancer cells. An increasing prevalence of cancer has also been reported in the country. As per the World Health Organization (WHO), in 2018, nearly 4.3 million new cancer incidences were reported in the country. 

Some key players in the market include AstraZeneca plc, Pfizer Inc., Innovent Biologics, Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Amgen Inc. The strategies that are implemented by the market players to expand market share include product launches and partnerships and collaborations. For instance, in December 2019, AstraZeneca declared that NMPA has granted marketing authorization for Imfinzi (durvalumab) to treat patients with unresectable, Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (CRT). This approval represents the company’s long-standing commitment to improve the health outcomes of lung cancer patients in China. 

Research Methodology

The market study of the China monoclonal antibodies market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. China Monoclonal Antibodies Market Research and Analysis by Source
2. China Monoclonal Antibodies Market Research and Analysis by Application

The Report Covers

• Comprehensive research methodology of the China monoclonal antibodies market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the China monoclonal antibodies market.
• Insights about market determinants which are stimulating the China monoclonal antibodies market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.